Zhejiang Xianfeng Technology Group Co.,LTD., is mainly engaged in pharmaceutical intermediates and transition to the enterprise production of drugs, the company was founded in 2002, is located in the national historical and cultural city -- Linhai. Company covers an area of about 300 acres, with self import and export rights, 2010 sales have exceeded 250000000 yuan. Company existing staff 500 people, high education level and senior engineer with doctorate, master's senior titles such as the composition of the various types of technical personnel. The company has been awarded the "Zhejiang province science and Technology Department of Zhejiang province science and technology oriented small and medium-sized enterprises", "high-tech enterprises in Zhejiang province"; is the outstanding industrial enterprises in Linhai city; Linhai was City Hall columnto be listed the key enterprises. Under the jurisdiction of a wholly owned subsidiary - Zhejiang Wei Feng Pharmaceutical Co Ltd.Companies adhere to market - oriented, innovation and development, quality of survival of the concept of management, strengthening the management of enterprises; has a high quality, strong development ability and rich experience in the production of professional technical team; has a modern R & D center and test center; have all kinds of 10 patents; products of advanced production technology and equipment excellent, perfect detection means. Companies with domestic relevant universities, research institutes and some well-known enterprises is closely linked to. The company continued to develop new products, to meet the needs of domestic and foreign markets, products sold at home and abroad market, well received by customers. The company spirit of "quality, innovation lead" and the spirit of "mutual benefit and common development" principle, wholeheartedly provide the high quality products and service for customers at home and abroad.At present the company's products are mainly anti infection drug intermediates, are developing anti tumor drugs intermediates and sartan drug. The company will further consolidate and strengthen the technical and cost advantages of existing products, at the same time to anti infection drugs, antihypertensive drugs, antineoplastic drugs for the direction of development, increase the investment in product research and development, and constantly develop new products, improve the construction of the industrial chain, expanding the scale of the main products, to enhance the core competitive ability, gradually become the important influence supplier. The enterprise bigger and stronger, the realization enterprise change from the production of pharmaceutical intermediates to produce APIs, realize the long-term and stable development of the company.